Get the composition of our in-house portfolios

All portfolios and performance
Portfolio Ref: EQ3520LO1M
Performance in the last:
Follow this Portfolio
1D 0.0 %
1W -0.3 %
2W -0.5 %
1M 1.1 %
3M 0.6 %
6M 4.3 %
9M 4.5 %
1Y 13.4 %
Alpha
2.0%
Beta
0.62
sharpe-R
0.75
Benchmark
SP500 (SPDR S&P 500 ETF Trust)
sharpe-R Benchmark
1.8
The portfolio metrics Alpha, Beta and Sharpe Ratio are computed using a risk free rate of 0%.
Other Information
Calculation Frequency Daily
Latest Valuation Time 2025-02-18 07:01:01
Launch Date 2023-01-01 00:00:00
First Valuation Date 2021-01-01 00:00:00
Max. DrawDown -10.59%
Max. DrawDown Benchmark -8.41%

This Long Only strategy aims to find promising assets to invest in for a maximum holding period of 1 Month in the Equity asset class. This portfolio focuses only on companies in the Health Care sector. The maximum number of assets that can be allocated in this strategy is 20.

The assets selection in this portfolio is based on: Macro-Pattern Mix St..
Please note that all model portfolios assume that the entry price for each trade is the previous close price.

Portfolio Performance against the market Benchmark

Try Our Peformance Checker Tool

Risk Level
2
Difficulty Level
2

Do you want to invest in this strategy ?

Follow the portfolio and you will get notified for every change in the composition of the portfolio

Current Portfolio Composition

No Asset in the portfolio
The percentage of cash held in the portfolio is: 100%
** The description of each asset is available Here

The latest 5 Compositions change

2025-02-17 00:00:00 : Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is: 100%
New Assets Added
None
Assets Removed
Asset Action Perf %
MD Sell All 0.36%
NVRO Sell All 34.67%
LGND Sell All 8.81%
RGNX Sell All -1.88%
ANIP Sell All 4.19%
ORGO Sell All 11.11%
Assets Rebalanced
None
2025-02-14 00:00:00 : Portfolio change date
Asset Action Weight PnL
MD Pediatrix Medical Group, Inc. Buy 4.97% 3.36%
NVRO Nevro Corp. Buy 6.49% 34.91%
LGND Ligand Pharmaceuticals Incorporated Buy 4.97% 3.31%
RGNX REGENXBIO Inc. Buy 4.74% -1.61%
ANIP ANI Pharmaceuticals, Inc. Buy 5.04% 4.67%
ORGO Organogenesis Holdings Inc. Buy 5.13% 10.51%
The percentage of cash held in the portfolio is: 68.66%
New Assets Added
None
Assets Removed
Asset Action Perf %
ACRS Sell All -12%
Assets Rebalanced
None
2025-02-13 00:00:00 : Portfolio change date
Asset Action Weight PnL
ACRS Aclaris Therapeutics, Inc. Buy 4.19% -13.2%
MD Pediatrix Medical Group, Inc. Buy 4.91% 1.79%
NVRO Nevro Corp. Buy 6.51% 34.91%
LGND Ligand Pharmaceuticals Incorporated Buy 4.88% 1.01%
RGNX REGENXBIO Inc. Buy 4.67% -3.23%
ANIP ANI Pharmaceuticals, Inc. Buy 5.1% 5.53%
ORGO Organogenesis Holdings Inc. Buy 5.12% 9.91%
The percentage of cash held in the portfolio is: 64.62%
New Assets Added
None
Assets Removed
Asset Action Perf %
AXGN Sell All -2.52%
Assets Rebalanced
None
2025-02-12 00:00:00 : Portfolio change date
Asset Action Weight PnL
AXGN AxoGen, Inc. Buy 4.62% -4%
ACRS Aclaris Therapeutics, Inc. Buy 4.24% -12%
MD Pediatrix Medical Group, Inc. Buy 5.05% 4.86%
NVRO Nevro Corp. Buy 6.5% 34.91%
LGND Ligand Pharmaceuticals Incorporated Buy 4.93% 2.26%
RGNX REGENXBIO Inc. Buy 4.75% -1.48%
ANIP ANI Pharmaceuticals, Inc. Buy 5.1% 5.84%
ORGO Organogenesis Holdings Inc. Buy 5.03% 8.41%
The percentage of cash held in the portfolio is: 59.78%
New Assets Added
None
Assets Removed
Asset Action Perf %
DNLI Sell All -4.28%
AXSM Sell All 41.01%
CERS Sell All -9.19%
Assets Rebalanced
None
2025-02-11 00:00:00 : Portfolio change date
Asset Action Weight PnL
AXGN AxoGen, Inc. Buy 4.65% -2.9%
ACRS Aclaris Therapeutics, Inc. Buy 4.58% -4.4%
MD Pediatrix Medical Group, Inc. Buy 4.79% -0.14%
NVRO Nevro Corp. Buy 6.47% 34.91%
LGND Ligand Pharmaceuticals Incorporated Buy 4.96% 3.48%
AXSM Axsome Therapeutics, Inc. Buy 6.5% 35.55%
CERS Cerus Corporation Buy 4.48% -6.49%
DNLI Denali Therapeutics Inc. Buy 4.66% -2.88%
RGNX REGENXBIO Inc. Buy 5.09% 6.05%
ANIP ANI Pharmaceuticals, Inc. Buy 5.05% 5.38%
ORGO Organogenesis Holdings Inc. Buy 4.96% 7.21%
The percentage of cash held in the portfolio is: 43.81%
New Assets Added
None
Assets Removed
Asset Action Perf %
AGEN Sell All -15.67%
INSM Sell All 13.33%
ATXS Sell All -10.14%
Assets Rebalanced
None
2025-02-10 00:00:00 : Portfolio change date
Asset Action Weight PnL
AXGN AxoGen, Inc. Buy 4.72% -1.59%
INSM Insmed Incorporated Buy 5.56% 15.99%
ACRS Aclaris Therapeutics, Inc. Buy 4.78% -0.4%
MD Pediatrix Medical Group, Inc. Buy 4.67% -2.64%
NVRO Nevro Corp. Buy 6.47% 34.91%
LGND Ligand Pharmaceuticals Incorporated Buy 5.01% 4.45%
AXSM Axsome Therapeutics, Inc. Buy 5.41% 12.81%
CERS Cerus Corporation Buy 4.43% -7.57%
DNLI Denali Therapeutics Inc. Buy 4.96% 3.49%
ATXS Astria Therapeutics, Inc. Buy 4.38% -8.73%
RGNX REGENXBIO Inc. Buy 5.29% 10.35%
ANIP ANI Pharmaceuticals, Inc. Buy 5.13% 7.07%
ORGO Organogenesis Holdings Inc. Buy 4.8% 3.9%
AGEN Agenus Inc. Buy 4.08% -8.62%
The percentage of cash held in the portfolio is: 30.3%
New Assets Added
None
Assets Removed
Asset Action Perf %
AORT Sell All 1.06%
MDXG Sell All -5.78%
BLFS Sell All -7.77%
Assets Rebalanced
None

Load more previous compositions

Compositions In The Last 2W Compositions In The Last 1M Compositions In The Last 3M Compositions In The Last 6M

Market Overview

Disclaimer Quantam Research does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, assets forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
Cookies Settings